Arovella Therapeutics financials at a glance

+ Portfolio

The revenue of Arovella Therapeutics is reported as 0.00041 billion Dollars in the fiscal year 2023. The earnings were -0.01 Dollars per share in 2023, which was 0 higher than 2022. And about 0 billion Dollars are reported as free cash flow in the financials of Arovella Therapeutics 2023. No dividends were paid to the shareholders of the Arovella Therapeutics stock ASX:ALA in the financial year 2023.

$0.41M

Revenue

$-0.01

Earnings Per Share

86.01%

Gross Margin %

$0.00M

Free Cash Flow

Revenue

0.41

Earnings Per Share

-0.01

Gross Margin %

86.01

Free Cash Flow

0.00

Financials

Year	Year	TTM	2023	2022	2021	2020
Rev.	Revenue	N/A	$0.41M	$0.30M	$0.26M	$0.53M
GM %	Gross Margin %	86.01%	86.01%	30.00%	75.29%	82.05%
OM	Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	Earnings Per Share	$-0.01	$-0.01	$-0.01	$-0.01	$-0.03
Div.	Dividends	N/A	$0.00	$0.00	$0.00	$0.00
PR %	Payout Ratio %	0	0	-0.00%	-0.00%	-0.00%
Sha.	Shares	N/AM	849.91M	669.84M	480.82M	142.25M
OCF	Operating Cash Flow	N/A	$0.00M	$0.00M	$0.00M	$0.00M
FCF	Free Cash Flow	N/A	$0.00M	$0.00M	$0.00M	$0.00M
FCFS	Free Cash Flow Per Share	$-0.01	$-0.01	$-0.01	$-0.01	$-0.02

Arovella Therapeutics financials at a glance

Financials

Discover